Primitive Neuroectodermal Tumor — Trials

Primitive Neuroectodermal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 146
Recruiting: 80
Ph III recruiting: 8
Growth YoY: −33.3%
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06047535	Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.	not yet recruiting	Phase 4	62	SciClone PharmaceuticalsINDUSTRY	0	Sep 21, 2023	clinicaltrials

Data updated 22 days agoSource updated Sep 21, 2023source: clinicaltrials